Market Currents
Shares of BioCryst Pharmaceuticals (BCRX -30%) react hard to yesterday's announcement, hitting...
-
Wednesday, October 31, 2012, 2:07 PM ETShares of BioCryst Pharmaceuticals (BCRX -30%) react hard to yesterday's announcement, hitting new 52-week lows after the drug-maker withdrew its Investigational New Drug application for its antiviral nucleoside treatment for hepatitis C, BCX5191. The FDA has raised concerns related to the drug's preclinical toxicity profile at levels necessary for it to be effective.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
